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Abstract
Introduction: The Vb12-transgenic mouse was previously generated to investigate the role of antigen-specific T
cells in collagen-induced arthritis (CIA), an animal model for rheumatoid arthritis. This mouse expresses a transgenic
collagen type II (CII)-specific T-cell receptor (TCR) b-chain and consequently displays an increased immunity to CII
and increased susceptibility to CIA. However, while the transgenic Vb12 chain recombines with endogenous a-
chains, the frequency and distribution of CII-specific T cells in the Vb12-transgenic mouse has not been
determined. The aim of the present report was to establish a system enabling identification of CII-specific T cells in
the Vb12-transgenic mouse in order to determine to what extent the transgenic expression of the CII-specific b-
chain would skew the response towards the immunodominant galactosylated T-cell epitope and to use this system
to monitor these cells throughout development of CIA.
Methods: We have generated and thoroughly characterized a clonotypic antibody, which recognizes a TCR
specific for the galactosylated CII(260-270) peptide in the Vb12-transgenic mouse. Hereby, CII-specific T cells could
be quantified and followed throughout development of CIA, and their phenotype was determined by
combinatorial analysis with the early activation marker CD154 (CD40L) and production of cytokines.
Results: The Vb12-transgenic mouse expresses several related but distinct T-cell clones specific for the
galactosylated CII peptide. The clonotypic antibody could specifically recognize the majority (80%) of these.
Clonotypic T cells occurred at low levels in the naïve mouse, but rapidly expanded to around 4% of the CD4
+ T
cells, whereupon the frequency declined with developing disease. Analysis of the cytokine profile revealed an early
Th1-biased response in the draining lymph nodes that would shift to also include Th17 around the onset of
arthritis. Data showed that Th1 and Th17 constitute a minority among the CII-specific population, however,
indicating that additional subpopulations of antigen-specific T cells regulate the development of CIA.
Conclusions: The established system enables the detection and detailed phenotyping of T cells specific for the
galactosylated CII peptide and constitutes a powerful tool for analysis of the importance of these cells and their
effector functions throughout the different phases of arthritis.
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Collagen-induced arthritis (CIA) is the most commonly
used animal model for rheumatoid arthritis. Develop-
ment of CIA is dependent on both B cells and T cells.
The major role of B cells is to produce collagen type II
(CII)-specific antibodies, and passive transfer of such
antibodies has the capacity to bind cartilage in vivo and
induce an acute arthritis. A major role of T cells is to
aid B cells in their production of anti-CII antibodies,
but they are also believed to play an active part in the
disease via activation of other cell types, such as synovial
macrophages. The influence of T cells in established
CIA, however, is less clear. Adoptive transfer of CII-spe-
cific T cells alone does not induce clinical disease but
may lead to microscopic synovitis [1]. Adoptive transfer
of CII-specific T cells has also been shown to prolong
the otherwise acute arthritis induced by passive transfer
of CII antibodies [2].
The use of T-cell receptor transgenic (TCR-tg) mice
has proven a powerful tool for investigating the nature
of self-reactive T cells in tolerance and autoimmunity
[3]. To further facilitate the understanding for the role
of T cells in CIA, three different CII-specific TCR-tg
mouse strains have earlier been described and shown to
display an accelerated onset of severe arthritis, com-
pared with nontransgenic littermates. Transgenic T cells
from all three strains are A
q-restricted and recognize
the same region on CII that is located between amino
acid positions 260 and 270. This region harbors a lysine
residue at position 264, which is naturally subjected to
post-translational modifications, through hydroxylation
and subsequent glycosylation. Strikingly, each of the
three previously described TCR-tg mouse strains in fact
recognize different forms of the CII(260-270) epitope,
where the Va11.1/Vb8.3-tg mouse [4], the Va11.1/
Vb8.2-tg mouse [5] and the Vb12-tg mouse [6] respond
to the nonmodified [4], the hydroxylated [7] and the
galactosylated [8] CII(260-270) peptide, respectively.
Although each of the mentioned post-translationally
modified peptides has its importance in A
q-restricted
CIA, we have earlier shown that glycosylation of CII is
of major importance for T-cell tolerance and pathology
in CIA [9]. We therefore found it important to establish
an animal model that would allow for identification and
tracking of T cells specific for the galactosylated CII
peptide. In contrast to the Va11.1/Vb8.3-tg and
Va11.1/Vb8.2-tg mouse strains, however, which express
both the a-chains and b-chains of the TCR as trans-
genes, the galactosylated CII-specific Vb12-tg mouse is
only transgenic for the CII-specific b-chain, which may
combine with any endogenous a-chain. Although the
Vb12-tg mouse displays an increased T-cell and B-cell
immunity to CII and is more susceptible to CIA, it
cannot be assumed that all, or even the majority, of
CD4
+ T cells are CII specific, as was the case for the
Va11.1/Vb8.3-tg and Va11.1/Vb8.2-tg mouse strains.
Indeed, the Vb12-tg mouse can also develop immunity
against microorganisms as well as immunity to tubercu-
lin-purified protein derivative, an immunogenic compo-
nent of complete Freund’s adjuvant (CFA) [6,8].
In the present report we have therefore established
and thoroughly characterized a clonotypic antibody,
which recognizes a TCR specific for the galactosylated
CII(260-270) peptide in the Vb12-tg mouse. Using this
antibody we were able to describe the emerging T-cell
response and its transition in Vb12-tg mice following
challenge with CII.
Materials and methods
Mice
To generate [B10.Q × DBA/1]F1 mice transgenic for
Vb12, B10.Q mice were crossed with DBA/1 mice,
expressing a transgenic TCR b-chain (Vb12), obtained
from a CII-specific T-cell clone, originally derived from
a CII-immunized DBA/1 mouse [6]. All animals were
between 7 and 12 weeks of age at the start of the
experiments. Mice were housed in a conventional ani-
mal facility and all experiments were performed accord-
ing to the Swedish ethical committee guidelines.
Antigens
The rat CII was obtained from pepsin-digested SWARM
chondrosarcoma [10], and subsequently processed as
previously described [11]. CII peptides, containing the
259 to 273 sequence of rat CII with a nonmodified
lysine at position 264 (K264) or with a b-D-galactopyra-
nosyl residue on L-hydroxylysine at position 264 (Gal-
HyK264), were synthesized as previously described [12].
Production of the recombinant 22a1-7E T-cell receptor
protein
Total RNA of the murine T-cell hybridoma clone 22a1-
7E was extracted and cDNA synthesis was performed
following standard protocols. The V-gene segments
encoding the Va16 and Vb12 chains of the 22a1-7E
TCR were amplified by PCR using sequence-specific pri-
mers. Following an earlier-described method for genera-
tion of single-chain Fv antibodies [13], we used an
assembly PCR strategy to connect the Va16 segment
and the Vb1 2s e g m e n tb yaf r a g m e n te n c o d i n gag l y -
cine-serine-linker (-(GSSS)4-) and cloned the entire con-
struct into the pTriEx-1.1 vector (Merck, Darmstadt,
Germany).
Upon control by nucleotide sequencing, the respective
construct was transformed into Origami™ (DE3)pLacI
cells (Merck, Darmstadt, Germany) for bacterial
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purified from inclusion bodies of the lyzed bacteria by
affinity chromatography on a Co
2+-affinity resin (Takara
Bio Europe/Clontech, Saint-Germain-en-Laye, France).
The purification was performed according to the manu-
facturer’s instructions and the protein was eluted with
150 mM imidazole buffer containing also 6 M guanidi-
nium hydrochloride, 50 mM sodium phosphate, 500
mM NaCl, 3 mM b-mercaptoethanol, pH 7.8. Purified
fractions of the denatured TCR protein were pooled and
diluted to 300 μg/ml for the subsequent refolding proce-
dure, consisting of repetitive dialysis steps. A mixture of
0.5 mM GSSH and 5 mM GSH was added and stirred
for 1 hour at 4°C. The preparation was subsequently
dialyzed for two sequential 16-hour intervals in 100 mM
Tris, 400 mM arginine, 2 mM b-mercaptoethanol,
2m ME D T A ,p H8 . 0a n d1 0 0m MT r i s ,2 0 0m M
arginine, 2 mM b-mercaptoethanol, 2 mM EDTA, pH
8.0. Subsequently, the buffer was changed to 20 mM
Tris, 150 mM NaCl, 1 mM b-mercaptoethanol, 2 mM
EDTA, pH 8.0 and the dialysis procedure continued for
another 32 hours (2 × 16 hours).
Homogeneity of the respective preparations was
demonstrated by the detection of a single protein band
with an electrophoretic mobility corresponding to calcu-
lated molecular mass in 14% acrylamide gels upon Coo-
massie Blue staining.
Generation of a monoclonal antibody specific for the
22a1-7E T-cell receptor
To generate clonotypic antibodies, E3 rats were immu-
nized with a recombinant 22a1-7E TCR protein in CFA
(Difco, Detroit, MI, USA). The 22a1-7E TCR originates
from a T-cell clone, specific for the galactosylated CII
(260-270) epitope, isolated from a CII-immunized Vb12-
tg mouse. Lymph node cells from E3 rats immunized
with the 22a1-7E TCR protein were prepared 10 days
after immunization and were fused with myeloma cells
(P3X63-Ag8.653) as described previously [14]. Superna-
tant from growing cultures was tested for staining of the
22a1-7E T cell hybridoma clone (Va16/Vb12; RB,
unpublished data), HCQ.3 (Va16/Vb8[ 1 5 ] )a n dH C Q . 4
(Va4/Vb12 [15]). Cells producing antibodies that
stained 22a1-7E, but not HCQ.3 or HCQ.4 hybridomas,
were selected for expansion, subcloning and retesting.
After two additional rounds of selections, one clone spe-
cific for the 22a1-7E TCR of the IgG1 isotype was
obtained and was denoted B22a1.
Antibodies and flow cytometry analysis
The TCR binding specificity of B22a1 and the expres-
sion level of TCR on the surface of T-cell hybridoma
was determined by flow cytometry using the following
antibodies and reagents: B22a1-bio (produced from our
in-house collection), TCR cb-bio (clone H57-597; in-
house collection) and propidium iodide (Invitrogen,
E u g e n e ,O r e g o n ,U S A ) .S u b s e q u e n t l yb i o t i nw a s
detected by allophycocyanin-conjugated streptavidin (BD
Pharmingen, San Diego, CA, USA). The cells were then
acquired with a flow cytometer (FACSort; BD Bio-
sciences, San Jose, CA, USA) by gating on propidium-
iodide-negative live cells.
For determination of relative frequencies of B22a1
+
T cells, their activation and cytokine profile, the follow-
ing antibodies were used for extracellular staining: Anti-
Fcg receptor (2.4G2) and B22a1-bio from our in-house
collection; anti-CD11b-FITC (M1/70), anti-CD45R-FITC
(RA3-6B2), anti-MHC class II-FITC (7.16.17),
anti-CD49b-FITC (DX5), and antigen-presenting cell
(APC)-conjugated streptavidin from BD Pharmingen
(San Diego, CA, USA); and anti-CD4-PE-Cy5.5 (RM4-5)
from eBioscience (San Diego, CA, USA). For intracellu-
lar staining, the following antibodies were used: anti-
CD40L-PE (MRI), anti-IFNg-PE-Cy7 (GMX1.2) and
anti-IL-17-Pacific blue (TC11-18H10.9) purchased from
eBioscience (San Diego, CA, USA), and anti-IL2-Alexa
Fluor 700 (JES6-5H4) purchased from BioLegend (San
Diego, CA, USA).
All antibodies were titrated for optimal saturating con-
centration. For exclusion of dead cells, the LIVE/DEAD
Fixable Green Dead Cell Stain Kit (Invitrogen, Eugene,
Oregon, USA) was used. At least 1 × 10
5 Th cells were
acquired on a flow cytometer (FACS Aria/FACS LSRII;
BD Biosciences, San Jose, CA, USA) and were analyzed
using FlowJo software (Treestar, Inc. Ashland, OR,
USA).
For antigen-specific detection of CD154 (CD40L) and
cytokines, single-cell suspensions were processed as
described earlier by Frentsch and colleagues [16] with
some modifications. In brief, 1.2 × 10
7 cells/ml were
cultured for 6 hours in the presence of the galactosy-
lated CII peptide (GalHyK264, 10 μg/ml) and anti-CD28
(1 μg/ml, clone 61109; R&D Systems, Minneapolis, MN,
USA). For intracellular accumulation of CD40L and
cytokines, 2 μg/ml Brefeldin A (Sigma-Aldrich, St.
Louis, MO, USA) was added after 2 hours of culture.
The cells were then washed and stained for 15 minutes
at room temperature with the surface markers. After-
wards, the cells were fixed with Cytofix/Cytoperm solu-
tion (BD Pharmingen, San Diego, CA, USA) and
permeabilized with Perm/Wash buffer (BD Pharmingen,
San Diego, CA, USA) according to the manufacturer’s
instructions, and were stained for CD40L and cytokines.
Monoclonal antibody treatments and lymphocyte assay
The antibody B22a1 was purified from culture superna-
tant using gamma-bind plus sepharose gel matrix (GE
Healthcare, Uppsala, Sweden), dialyzed against PBS,
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tion was determined either spectrophotometrically (at
280 nm) or by freeze-drying.
For in vitro depletion, single-cell suspensions from
pooled popliteal and inguinal lymph nodes were pre-
pared 10 days post immunization. One-half of each sin-
gle-cell suspension was depleted of B22a1
+ Tc e l l s ,
whereas the remaining half was kept untouched on ice
for further processing. Briefly, lymphocytes were incu-
bated with biotinylated antibody B22a1 for 20 minutes
at 4°C. Subsequently, biotin binder Dynabeads (Invitro-
gen Dynal AS) were added according to the manufac-
turer’s recommendation and labeled cells were depleted
by placing the sample tubes in a magnetic stand. The
samples were depleted twice to reach a final purity >
95% before both the untouched and depleted fractions
were set up into triplicate cultures. The cells were sti-
mulated with antigen (lathyritic CII (pepsin-free), K264,
GalHyK264 and ConA) at a concentration of 10
6 cells/
well in microtiter plates and were incubated for
72 hours. One microcurie of methyl-[
3H]thymidine
(Amersham, GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK) was added to each well for an additional
15 to 18 hours. Cell proliferation was measured by
counting the incorporation of methyl-[
3H]thymidine.
For in vivo depletion, B22a1 was injected intraperito-
neally as a single dose of 240 μg/mouse. To increase the
depletion capacity, MAR18.5 was administered as a sec-
ondary antibody 1 hour after the primary antibody by
the same method in a dose of 340 μg [17]. The mono-
clonal antibodies were given at day 0 (4 hours before
immunization), day 6 or day 20, depending on the
experiment.
Induction and evaluation of CIA and anti-CII antibodies
Mice were injected by the base of the tail with 50 μl
emulsion consisting of 100 μg rat CII emulsified 1:1 in
CFA (Difco, Detroit, MI, USA). Development of clinical
arthritis was followed three times weekly through visual
scoring of the paws, starting 2 weeks after immuniza-
tion. The arthritis was scored using a scale ranging from
1 to 15 for each paw, with a maximum score of 60 per
mouse [18]. Each arthritic toe and knuckle was scored
as 1, with a maximum of 10 per paw. A score of 5 was
given to an arthritic ankle.
Blood samples were collected on days 17 and 35 for
determination of anti-CII antibody responses. The titers
of total anti-CII IgG as well as the IgG1,I g G 2a,I g G 2b
and IgM isotypes were determined through quantitative
ELISA [19], where serum was titrated (1:10 to 1:10
6)i n
parallel to the standard and titer values were interpo-
lated within the linear range and related to the standard
curve. Biotinylated rat anti-mouse IgG (clone
187.1; our collection) or peroxidase-conjugated goat
anti-mouse antibodies specific for IgM, IgG1 or IgG2a
(Southern Biotech, Birmingham, AL, USA) were used as
detecting antibodies. Binding of biotinylated antibodies
was revealed by Extravidin Peroxidase (Sigma-Aldrich).
Plates were developed using ABTS (Roche Diagnostics,
Mannheim, Germany) as substrate, and the absorbance
was measured at 405 nm (Synergy-2; BioTek, Winooski,
VT, USA). Total anti-CII IgG levels were measured (μg/
ml) using purified polyclonal anti-CII IgG antibodies of
a known concentration as a standard. Isotype levels
were measured as arbitrary concentrations using our
purified monoclonal anti-CII antibodies with known
isotype or pooled sera from arthritic mice.
T-cell hybridoma assays
All cells were cultured in DMEM + Glutamax-I (Gibco
Life Technologies, Grand Island, NY, USA) supplemen-
ted with 5% heat-inactivated FCS and penicillin/
streptomycin.
For antibody-induced T-cell hybridoma stimulation,
flat-bottomed microtiter 96-well plates (NUNC, Thermo
Fisher Scientific, Roskilde, Denmark) were precoated
with a titrated concentration of purified immunoglobu-
lins (B22a1, anti-TCR cb,a n t i - C D 4( c l o n eH 1 2 9 . 1 9 ) ,a l l
produced from in-house hybridomas) starting at 5 μg/
ml. Plates were then washed and 5 × 10
4/well T-cell
hybridoma were added and cultured for 24 hours, before
assaying the supernatant for IL-2 content.
For the inhibition of antigen-induced T-cell hyridoma
stimulation, 5 × 10
4/well T-cell hybridoma where pre-
incubated with a titrated concentration of purified
immunoglobulins (B22a1, anti-TCR cB (clone H57-597),
anti-CD4 (clone H129.19; our collection)) starting at 10
μg/ml in flat-bottomed microtiter wells in 50 μlm e d -
ium. After 1 hour of incubation at 37°C, the hybridoma
were washed twice with PBS and transferred to a pre-
viously prepared microtiter plate containing splenocytes
as APCs (5 × 10
5/well) and peptide (0.3 μg/ml). After 24
hours of incubation at 37°C, the supernatants were ana-
lyzed for IL-2.
To determine the stimulatory capacity of the clono-
typic antibody, the relative production of IL-2 between
nonstimulated and stimulated T-cell hybridoma clones
was determined by ELISA. Hereby, 50 μl supernatant
were removed from the plates after 24 hours of cul-
ture. For detection, Jes6-1A12 (5 μg/ml; our collection)
and Jes6-5H4-biotin (2 μg/ml; Mabtech, Nacka Strand,
Sweden) were used as the capture antibody and detec-
tion antibody, respectively. Binding of biotinylated
antibodies was revealed by Europium-labeled streptavi-
din (PerkinElmer Life Sciences, Inc. Boston, MA, USA)
and plates were analyzed using a Victor 1420 multi-
label counter (PerkinElmer Life Sciences, Inc. Boston,
MA, USA).
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Antibody levels and in vitro lymphocyte assays were
analyzed with the Mann-Whitney U test, whereas arthri-
tis severity was analyzed with Fisher’s exact test and the
flow cytometry data with an unpaired t test.
Results
Characterization of B22a1 specificity
The clonotypic antibody B22a1 was generated through
immunization of a rat with a recombinant protein, cor-
responding to the TCR of the 22a1-7E T-cell clone, ori-
ginating from a CII-primed DBA/1-Vb12-tg mouse. The
purified B22a1 antibody was tested for binding to the
22a1-7E T-cell hybridoma clone as well as to other A
q-
restricted and CII-specific clones sharing either one or
none of the TCR chains with the 22a1-7E clone (Va16/
Vb12). In addition, two more closely related T-cell
hybridoma clones (18b4-10 D and 3D4-1.2) were also
t e s t e d .T h et w ol a t t e rc l o n e sw e r ea l s oo b t a i n e df r o m
the DBA/1-Vb12-tg mouse and share both TCR a-
chains and b-chains with 22a1-7E, but differ at one sin-
gle amino acid within the complementarity determining
r e g i o n3( C D R 3 )r e g i o no ft h en o n t r a n s g e n i cV a chain
(RB, unpublished data).
The B22a1 antibody failed to stain the T-cell clones
not expressing a Va16 chain together with the trans-
genic DBA/1-Vb12-tg chain (HCQ.3, HCQ.4, HRC.2
and HM1R.2; Figure 1a). From the clones expressing the
DBA/1-Vb12-tg chain together with a closely related
Va16 chain, the B22a1 antibody stained the 22a1-7E
and 18b4-10 D T-cell clones strongly but not the 3D4-
1.2. Also, when normalizing the B22a1 staining against
the level of surface TCR expression, significant staining
was only observed against the 22a1-7E and 18b4-10 D
18b4-10D 3D4-1.2
HCQ.3 HM1R.2 HCQ.4 HRC.2
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B
Figure 1 B22a1 binding requires a combination of Vb12 and Va16 T-cell receptor chain. (a) Flow cytometric analysis of T-cell hybridoma
expressing different Va-chain and Vb-chain combinations stained with the biotinylated antibody B22a1 and allophycocyanin-conjugated
streptavidin. Histograms show the staining intensities of negative control (FMO; stained with allophycocyanin-conjugated streptavidin only),
B22a1 (straight line) for specificity and T-cell receptor (TCR) cb (dotted line) for TCR surface expression levels. (b) For stimulation, T-cell
hybridomas were cultured for 24 hours in precoated cell culture plates with titrated amounts of B22a1, TCR cb (positive control) and CD4
(negative control), whereupon IL-2 production was determined by ELISA. Ab, antibody; FU, fluorescence units.
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22a1-7E T-cell hybridoma clone (Table 1). Comparison
of the amino acid sequence within the CDR3 region of
the Va16 chain shows Met-106 (22a1-7E) and Tyr-108
(22a1-7E and 18b4-10D) to be involved in B22a1 recog-
nition, as substitution of these to either Ile-106 (18b4-
D10) or Asp-108 (3D4-1.2) leads to decreased and insig-
nificant antibody binding, respectively.
To test the stimulatory capability of the B22a1 anti-
body, T-cell hybridomas were incubated with precoated
B22a1 antibody and monitored for activation through
IL-2 production (Figure 1b). In agreement with the
staining data, B22a1 were highly effective in stimulating
the 22a1-7E and 18b4-10 D clones. B22a1 could also sti-
mulate the 3D4-1.2 clone at high concentration but
failed to activate CII-specific clones not expressing the
Va16/Vb12 TCR combination. In an inhibition assay,
the B22a1 antibody could also inhibit activation of the
22a1-7E and 18b4-10 D clones as well as partially block
activation of the 3D4-1.2 clone, but not that of unre-
lated clones (data not shown), again showing that the
B22a1 antibody is highly specific for the Va16/DBA/1-
Vb12-tg TCR combination. Finally, the B22a1 antibody
failed to stain A
q-restricted T cells from mice immu-
nized with control (non-CII) antigens as well as an A
q-
restricted T-cell hybridoma clone specific for pepsin
(see Additional file 1).
B22a1-binding T cells dominate CII-specific response in
Vb12-tg mice
Having shown that the B22a1 antibody recognizes CII-
specific T-cell clones obtained from CII-immunized
Vb12-tg mice, we next set out to determine the relative
frequency of T cells expressing the clonotypic determi-
nant among CII-reactive T cells in primed and non-
primed Vb12-tg mice. In nonimmunized Vb12-tg mice,
the frequency of B22a1
+CD4
+ T cells in peripheral
lymph nodes and spleen was 0.08%, compared with
around 0.007% in wildtype littermates (Figure 2a). Ten
days after immunization, the frequency in primed Vb12-
tg mice had increased to 4.5% of CD4
+ T cells in drain-
ing lymph nodes, while remaining at a low frequency of
0.1% in littermate controls.
To determine the relative frequency of B22a1
+CD4
+
T cells among the CII-reactive CD4
+ T cells we used
the expression of CD154 (CD40L) as a generic marker
of antigen-specific T cells [16]. Around 5 to 6% of CD4
+
T cells expressed CD40L upon restimulation in vitro
with the galactosylated CII peptide, and 70 to 80% of
t h e s ew e r ea l s op o s i t i v ef o rt h eB 2 2 a 1a n t i b o d y
(Figure 2b, middle panel). Roughly 20% of the B22a1
+
T cells did not express CD40L, however, and hence
appeared to remain in a nonactivated state (Figure 2b,
right panel). As expected, mice devoid of the transgenic
CII-specific Vb12 chain mounted a much weaker
immune response against the galactosylated CII peptide
upon restimulation in vitro, and only very few B22a1
+CD40L
+CD4
+ T cells were identified. As reported ear-
lier [8], the recall response of Vb12-tg mice was strongly
biased to the galactosylated CII peptide with only a
minimal response directed against the nonglycosylated
CII peptide (denoted K264; Figure 2b, left panel insert).
Nontransgenic littermates, on the other hand, mounted
a low but significant response to both peptides.
To further analyze the significance of B22a1
+ T cells
in Vb12-tg mice, lymph node cells from CII-primed
Vb1 2 - t gm i c ew e r ed e p l e t e do fB 2 2 a 1
+ T cells in vitro
and alteration in the CII-specific recall response was
subsequently determined (Figure 3). In vitro depletion of
B22a1
+ T cells resulted in a reduced recall response to
C I Ia n dt h eg a l a c t o s y l a t e dC I Ip e p t i d eb ya p p r o x i m a t e l y
80%, hence confirming the ex vivo data showing B22a1
+
T cells to predominate the CII-specific T-cell response
in Vb12-tg mice.
CII-specific T cells expand in the priming phase and
retract as the first arthritis symptoms appear
Having shown that the B22a1
+ T-cell population predo-
minates the CII-specific T-cell population in Vb12-tg
mice, we next analyzed the dynamics of antigen-specific
Table 1 Binding specificities of the B22a1 antibody towards different T-cell receptors
Clone TCR Va chain TCR Vb chain Antigen specificity SI TCR cb geometric mean SI normalized to TCR
a
22a1-7E 16 12 GalHyK264 24.0 110 218.1
18b4-10D 16 12 GalHyK264 12.3 431 28.6
3D4-1.2 16 12 GalHyK264 and GlcGalHyK264 1.1 431 2.5
HCQ.3 16 8.1 GalHyK264 0.1 357 0.2
HM1R.2 4 12 GalHyK264 0.9 505 1.7
HCQ.4 4 12 K264 0.1 316 0.3
HRC.2 2 20 K264 0.3 591 0.5
Table showing the staining index (SI) of B22a1 and the SI normalized to the T-cell receptor (TCR) expression, respectively. GalHyK264, CII(260-270) with a b-D-
galactopyranosyl residue on L-hydroxylysine at position 264; GlcGalHyK264, CII(260-270) with an a-D-glucopyranosyl-(1 > 2)-b-D-galactopyranosyl residue on L-
hydroxylysine at position 264; K264, CII(260-270) with a nonmodified lysine at position 264; TCR cb, anti-TCR cb antibody (clone H57-597).
a SI normalized to TCR
is multiplied by 1,000.
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Figure 2 B22a1
+ T cells dominate the collagen type II-specific T-cell expansion in Vb12 transgenic mice. Lymph nodes of naïve and
collagen type II (CII)-primed mice 10 days post immunization were restimulated for 6 hours in the presence of GalHyK264 and Brefeldin A. Flow
cytometry was subsequently performed to determine B22a1 frequencies and CD40L upregulation. (a) Dot plots show B22a1 mean frequency
among CD4 cells in Vb12-transgenic (Vb12-tg) mice (n = 5) and wildtype (WT) littermates (n = 4 and n = 5) left untreated (naïve) or immunized
10 days earlier. (b) Left panel: percentage of CD4 T cells upregulating CD40L upon restimluation with GalHyK264 in immunized Vb12-transgenic
mice and WT littermates. Insert: frequency of CD40L upregulation following stimulation with the nonmodified K264-peptide. Middle panel:
distribution of B22a1 staining among CD4
+CD40L
+ T cells. Right panel: quadrant gates of CD4-gated T cells. Numbers indicate frequencies (mean
± standard error of the mean) of two individual mice per group, reproduced in at least two independent experiments (b).
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Page 7 of 14T cells during CIA by determining the frequency of the
B22a1
+ T cells at different time points after induction of
CIA. To relate the frequency of antigen-specific T cells
to development of arthritis, a cohort of Vb12-tg mice
was immunized with CII and followed for clinical dis-
ease in parallel to the ex vivo analyses of representative
animals.
Immunization of Vb12-tg mice with heterologous CII
emulsified in CFA induced an onset of arthritis around
day 17 that rapidly progressed to severe disease within
the following 2 weeks (Figure 4, right y axis stars).
Ex vivo analyses clearly showed that CII priming at the
base of the tail triggered a primary immune response in
the draining inguinal lymph nodes, leading to an
increased frequency from initially 0.08% of B22a1
+CD4
+
T cells in nonimmunized animals up to 4.5% within the
first 10 days (Figure 4, left y axis). Twenty days post
immunization, however, the B22a1
+CD4
+ T-cell fre-
quency subsequently dropped again to 2.2% and slowly
stabilized around 1.7% at day 35 (Figure 4, left y axis). A
similar pattern could be observed in the spleen, albeit
with a somewhat lower frequency. Measurement of the
mesenteric lymph node, however, showed that only 0.2%
of B22a1
+CD4
+ T cells infiltrated this organ at peak day
10-indicating that the homing B22a1
+CD4
+ T cells did
not occur at random and that the mesenteric lymph
node is not involved in the arthritis-specific immune
mechanisms, since these cells had retracted to approxi-
mate base levels again at day 20. It was also possible to
detect significantly increased frequencies of B22a1
+
T cells in wildtype littermates 10 days after immunization
(Figure 4). Frequencies were profoundly reduced (0.1 and
0.3% in lymph nodes and spleen, respectively), however,
compared with those observed in Vb12-tg mice.
The anti-CII response is dominated by proinflammatory
cytokine producing B22a1
+ T cells during arthritis
To extend our analysis on the dynamics of CII-specific
Tc e l l si nV b12-tg mice during development of CIA, we
next investigated the activation status and production of
proinflammatory cytokines of CII-specific T cells at dif-
ferent time points after immunization with CII. We also
wanted to include B22a1
-CD4
+ T cells in these analyses
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Figure 3 In vitro depletion of B22a1
+ T cells reduces recall
response to collagen type II.V b12-transgenic mice were
immunized with collagen type II (CII) and 10 days later lymph node
cells were depleted of B22a1
+ T cells in vitro, and alterations in the
CII-specific [H
3]thymidine incorporation were noted after 4 days of
culture with lathyritic CII, K264 peptide, GalHyK264 peptide, medium
alone and ConA. Data show mean ± standard error of the mean of
four individual mice before and after depletion. *P < 0.05. CPM,
counts per minute.
0 5 10 15 20 25 30 35 40
0
1
2
3
4
5
6
7
0
10
20
30
40
50
WT LN
Vβ12 LN
WT spleen
Vβ12 spleen
WT mLN
Vβ12 mLN
Vβ12 mice (14)
days postimmunization
%
o
f
C
D
4
+
 
T
 
c
e
l
l
s
 
M
e
a
n
a
r
t
h
r
i
t
i
s
s
c
o
r
e
Figure 4 Collagen type II-specific T cells expand in priming phase and retract when arthritis symptoms appear. The indicated numbers
of Vb12-transgenic mice were immunized with collagen type II (CII) and were followed for development of arthritis (stars, referring to right y
axis). In parallel, frequencies of B22a1
+ T cells in CII-primed Vb12-transgenic mice and wildtype (WT) littermates were assessed by flow cytometry
in draining lymph nodes (LNs, open squares and closed circles), spleen (open and closed triangles) and mesenteric lymph node (mLN, open
circles and closed diamonds) (referring to left y axis). Data show the mean ± standard error of the mean of four individual mice (WT littermates),
five individual mice (Vb12-transgenic) and 14 individual mice (day 35).
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Page 8 of 14to ensure that our ex vivo data on the frequency of
B22a1
+CD4
+ T cells could be extrapolated to the whole
CII-specific T-cell repertoire in Vb12-tg mice. To
achieve this, CII-primed Vb12-tg mice were sacrificed at
three different time points during CIA. Pooled draining
lymph nodes and the spleen were then analyzed for
CD40L and cytokine expression in the priming phase
(day 10), shortly after arthritis onset (day 25) and,
finally, during severe clinical arthritis (day 35).
The CD40L expression in CD4
+ T cells followed the
same pattern as observed for the frequency of B22a1
+
CD4
+ T cells, with the most frequent expression
detected at day 10 and with fading frequencies at later
time points. Importantly, the B22a1
+CD4
+ T cells pre-
vailed as the predominant CII-specific T-cell population,
constituting 75 to 80% of all CD40L
+CD4
+ Tc e l l s ,
throughout the disease course (Figure 5a).
Having shown that the frequency of activated CII-spe-
cific T cells in the draining lymph nodes decline from
d a y1 0a n do n w a r d s( F i g u r e s4a n d5 a ) ,w ew e r ea l s o
interested in evaluating the quality of the CII-specific T-
cell response over time with regard to production of
proinflammatory cytokines, as these have previously
been found to dominate the response in Vb12-tg upon
immunization with CII in CFA [8,20]. We therefore
stratified the B22a1
+ and B22a1
- T-cell responses
according to their production of IL-2, IFNg and IL-17 to
detect whether the relative abundance of these cells
would shift over time among the CII-specific CD40L-
expressing T cells (Figure 5b). Indeed, stratification of
CII-specific T cells showed that both B22a1
+ and B22a1
-
Tc e l l sm o u n t e da nI F N g and IL-2 response that was
maintained in the draining lymph node from day 10
post immunization and throughout the development of
clinical arthritis. Compensating for the reduction in the
total frequency of CII-specific T cells from day 10
onwards (Figure 5a), however, showed that the fre-
quency of IL-2-producing and IFNg-producing T cells
among CD4
+ T cells was highest at the priming phase
(day 10) and then decreased with the progressing
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Figure 5 B22a1
+ T cells dominate during arthritis and are the main producers of proinflammatory cytokines.V b12-transgenic mice were
primed with collagen type II (CII) and lymphocytes were analyzed 10, 25 and 35 days after immunization, following 6 hours of restimulation in
the presence of the GalHyK264 peptide and Brefeldin A. (a) Representative dot plot from day 35 analysis and a summarizing bar graph showing
the frequencies of CD4
+ T cells being B22a1
-and B22a1
+ and expressing CD40L. (b) Cytokine production of activated CII-specific T cells,
determined by gating on total CD40L
+CD4
+ T cells. Bars represent mean percentage (± standard error of the mean) of cytokine-producing cells
among CD4
+CD40L
+ T cells, stratified according to B22a1 expression. IL-2 bars show frequency of cells producing IL-2 only, whereas IFNg and IL-
17 bars include IFNg and IL17 single positives as well as IFNg/IL-2 and IL-17/IL-2 double positives, respectively. The IFNg and IL-17 bars are not
adjusted for IFNg/IL-17 double-positive cells due to their low abundance. All plots include 12 mice, eight mice and five mice for day 10, day 25
and day 35, respectively. *P < 0.05, **P < 0.01, ***P < 0.001.
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Page 9 of 14arthritis in both B22a1
+ and B22a1
- CD4
+ T cells (data
not shown). In marked contrast, CII-specific IL-17 pro-
ducing T cells occurred with low frequency in the prim-
ing phase and instead peaked at the time of disease
onset whereupon the frequency dropped again to low
levels by the time of severe disease (Figure 5b). This
delay in occurrence was further emphasized by compar-
ing the frequency of IL-17-producing T cells among
CD4
+ T cells (data not shown).
Importantly, cytokine production was only detected in
cells that had upregulated CD40L. In addition, on aver-
age 0.4%, 1.6% and 0.6% of the CD40L-expressing
T cells were found to produce both IL-17 and IFNg dur-
ing the priming, disease-onset and later phases, respec-
tively (data not shown). Determination of the frequency
of IL-2-producing, IL-17-producing and IFNg-producing
T cells, however, could only account for 20 to 35% of
the total CII-specific T-cell population. These data col-
lectively show that, following priming in vivo,t h eC I I -
specific T-cell response in the draining lymph nodes is
initially dominated by Th1. As the overall T-cell
response subsequently fades, however, the T-cell
response shifts to also include Th17 by the time of
onset of clinical disease. Still, 60 to 85% of the antigen-
specific response could not be accounted for by
measuring the production of IL-2, IL-17 and IFNg. This
observation suggests that additional effector and regula-
tory functions are probably operating through the
remaining CII-specific T cells in order to control the
progression and regulation of disease.
Data thus far suggest that both B22a1
+ and B22a1
-
CD4
+ T cells could be involved in the development of
CIA in Vb12-tg mice. To confirm this, we depleted
B22a1
+CD4
+ Tc e l l sin vivo prior to immunization with
CII and subsequently observed the mice for alternation
in the development of CIA. Indeed, in vivo treatment
with the B22a1 antibody was efficient in depleting
B22a1
+CD4
+ T cells, as only very few B22a1
+ T cells
could be identified in the spleen and lymph nodes by
the end of the arthritis experiment (Figure 6b) and
caused a delay in disease onset (P < 0.05; Figure 6a). In
agreement with clinical disease, analysis of the anti-CII
antibody titers from the experiments also showed an
initial delay of antibody production that was later recov-
ered as arthritis had developed (Figure 6c).
We also investigated IgM, IgG1,I g G 2a and IgG2b anti-
CII antibodies following antibody treatment, to see
whether depletion of B22a1
+CD4
+ T cells would result
in a skewing in the quality of the antibody response. A
significant reduced IgM response was observed in mice
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Figure 6 Efficient depletion of B22a1
+ T cells before arthritis onset has limited effect on clinical disease. (a) The indicated numbers of
Vb12-transgenic male mice were treated with B22a1 and MAR18.5 antibodies 4 hours prior to immunization with collagen type II (CII) and
followed for development of arthritis. (b) Frequencies of B22a1
+ T cells by the end of the arthritis experiment were assessed by flow cytometry
in the lymph nodes and spleen. (c) Anti-CII IgG antibody levels at days 17 and 35 after immunization are shown as box plots. (d) Scatter plot
showing the frequencies of CD4
+ T cells being B22a1
- and B22a1
+ and expressing CD40L after 6 hours of restimulation in the presence of the
GalHyK264 peptide and Brefeldin A by the end of the arthritis experiment at day 35. *P < 0.05, **P < 0.01, ***P < 0.001.
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+CD4
+ T cells on day 17 (P = 0.009)
but not on day 35 (P = 0.75; data not shown). Even
though levels of anti-CII IgG1,I g G 2a and IgG2b levels
were uniformly reduced in depleted mice at day 17, the
differences did not reach statistical significance (P =
0.178, P = 0.082 and P = 0.125 for IgG1,I g G 2a and
IgG2b, respectively; data not shown). Analysis of the fre-
quency of CII-specific T cells by the end of the arthritis
e x p e r i m e n t ss h o w e dt h a tt h eB 2 2 a 1
-CD4
+ T cells in
depleted mice had expanded compared with nontreated
control mice (P = 0.038). Together with the data on
antibody isotype levels and the stratified cytokine pro-
files, this suggests that B22a1
- and B22a1
+ T cells exhi-
bit similar qualitatively effector functions and that
B22a1
- T cells indeed could take over the role of the
depleted B22a1
+ T cells in Vb12-tg mice (Figure 6d).
Discussion
The galactosylated CII(260-270) peptide has been shown
to constitute the immunodominant T-cell epitope in
A
q-expressing mice [12,15], and T cells specific for the
galactosylated variant of the CII(260-270) epitope have
been shown to be of major importance for development
of arthritis [9]. In the present report, we have used the
Vb12-tg mouse to establish a system where it is possible
to track T cells specific for galactosylated CII peptide.
The Vb12-tg mouse is so far the only described TCR-tg
mouse with increased cellular immunity to galactosy-
lated CII and increased susceptibility to CIA [6,8].
Despite the transgenic Vb12 chain being expressed on
virtually all CD3
+ T cells, however, it may still recom-
bine freely with endogenously derived a-chains, and the
frequency of CII-specific T cells in the Vb12-tg mouse
was therefore not known.
Recombinant MHC class II tetramers/multimers pre-
senting CII peptides have previously been used to iden-
tify CII-specific T cells ex vivo in A
q-expressing [21,22],
DR4-expressing [23], and DR1-expressing mice [24].
Successful identification of CII-specific T cells in A
q-
expressing mice, however, required that the CII peptide
had been covalently linked to the recombinant MHC
class II molecule. Covalent linkage of the peptide is
used in order to increase the stability of the CII peptide:
MHC class II molecule complex [25]. This is presently
not a realistic option for the galactosylated CII peptide
as hydroxylation of lysine residues of recombinant CII is
absent or poor in prokaryotic, yeast and insect cell sys-
tems [26,27] but is necessary for subsequent galactosyla-
tion of hydroxylysine residues. Because of the poor
feasibility to detect galactosylated CII-specific T cells
using the MHC class II tetramer technology, we instead
decided to generate a clonotypic antibody recognizing
T cells specific for the galactosylated CII peptide in the
Vb12-tg mouse. Hereby we could show that B22a1
+
T cells constitute only a minority of the total TCR
repertoire. Still, by performing depletion experiments
in vitro and through combinatory analysis of the fre-
quencies of clonotypic T cells and the activation status
of the total CII-specific T-cell population ex vivo,w e
found that the B22a1 antibody recognizes the vast
majority of the CII-specific T cells in Vb12-tg mice.
The frequency of B22a1
+ T cells in naïve Vb12-tg
mice (~0.1%) was found to be considerably lower than
that reported for other TCRb-tg mice using MHC class
II tetramer/multimers (1 to 3% [28-30], but still around
10 times higher than in wildtype littermates). This is a
considerably higher frequency than that estimated for a
specific T-cell clone in a naïve wildtype mouse [31], but
may partly be explained by the fact the B22a1 antibody
could recognize T cells with closely related but distinct
TCRs.
Following priming of Vb12-tg mice with CII in vivo,
we observed a 50-fold increase in the frequency of
B22a1
+ T cells - and the majority (80%) of, but not all,
B22a1
+ T cells would acquire an activated phenotype.
While our data consistently indicated CII-specific B22a1
+ and B22a1
- T cells to exhibit almost identical pheno-
types and only differ in their frequency of occurrence, it
may be assumed that a similar proportion of nonacti-
vated T cells can be found within the CII-specific
B22a1
- fraction. The lack of activation in 20% of the
cells is probably explained by the nonphysiological fre-
quency of CII-specific T cells, leading to competition for
APCs, as has been demonstrated in other studies
[32-34]. Owing to the limited number of APCs and the
accessibility of MHCs and costimulatory molecules
in vitro, a more stringent selection for activation may be
imposed despite an excess of the galactosylated CII
peptide.
Our results support an important role for CII-specific
T cells in the early phase of the arthritogenic immune
response (reviewed in [35]), where depletion of the pre-
dominant B22a1
+ T-cell population caused a delayed
onset of clinical arthritis. CII-specific T cells not tar-
geted by the clonotypic antibody were found to expand
rapidly and to partially replace the depleted B22a1
+ T-
cell subset, however, which was also evident when ana-
lyzed at the end of the arthritis experiment. It is of note
that depletion with the B22a1 antibody before priming
with CII caused a strong and rapid as well as longlasting
r e d u c t i o ni nt h ef r e q u e n c yo fB 2 2 a 1
+ T cells. We found
no evidence that antibody treatment would cause TCR
downregulation, as has been shown for gδ-T cells after
treatment with a monoclonal antibody specific for the
constant region of the gδ-TCR and which caused down-
regulation of the TCR and generation of persistent invi-
sible clones with reduced responsiveness [36] (data not
shown). Moreover, the monoclonal antibody MAR18.5
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increase the depletion capacity as previously shown [17].
Finally, sham-operated and thymectomized mice sub-
jected to antibody treatment and subsequent immuniza-
tion appeared equally protected from CIA, compared
with nondepleted mice, excluding a role for recent
B22a1
+CD4
+ thymic emigrants in the later-occurring
arthritis (data not shown). Taking these observations
together, therefore, CII-specific B22a1
- T cells that are
n o td e p l e t e db yt h eB 2 2 a 1a n t i b o d ys e e mt ob es u f f i -
cient to trigger CIA.
Although not conclusively demonstrated, an active
role for CII-specific T cells during clinical arthritis is
indirectly supported by their presence in the arthritic
joints [23,24], and also by experimental therapies specifi-
cally targeting Th1 and Th17 during active CIA [35,37].
The inability of the clonotypic antibody to recognize all
CII-specific T cells in the Vb12-tg mouse, however, pre-
vented us from addressing the role of T cells in the later
phases of arthritis development, by means of T-cell
depletion studies. Depletion of B22a1
+ T cells after
immunization with CII caused an even more rapid
expansion (within days) of CII-specific B22a1
- T cells,
and the depletion of B22a1
+ T cells was found to be less
efficient in draining lymph nodes, compared with the
spleen or blood (data not shown). Using combinatorial
analysis of expression of the early activation marker
CD40L and intracellular cytokines ex vivo, however, we
could determine the frequency of CII-specific T cells as
well as their cytokine profile at different time points
after induction. Our data clearly showed that the fre-
quency of CII-specific T cells peaked before onset of
clinical disease. In line with this, the frequency of IFNg-
producing CII-specific T cells among CD4
+ Tc e l l sa l s o
peaked before onset of clinical arthritis and subse-
quently declined with progression of disease. In contrast,
the frequency of CII-specific IL-17-producing T cells
among CD4
+ T cells was less abundant in the early
response, and instead increased in frequency to peak at
the time of disease onset.
T h er o l eo fI F N g in CIA is complex and has been
associated with both proinflammatory and regulatory
functions [38-41], and more recent reports have chal-
lenged the concept that CIA is a Th1-mediated disease
and have instead suggested the model to be more
dependent on Th17 [42-45]. While determined ex vivo
at the level of antigen-specific T cells, our findings on
the relative abundance of IFNg-responding and IL-17-
responding T cells over time add support to the recent
report by Lamacchia and colleagues in which investiga-
tions of the recall responses of bulk lymph node cells to
CII in CIA indicated a shift from an initially dominant
Th1 response to a mixed Th1/Th17 response [46].
Determining the role of CII-specific Th1 and Th17 in
mediating effector functions and regulating the initiation
or progression of CIA is challenging, however, as the
lymphoid response varies over time and between lym-
phoid organs and the joints [47,48]. These factors,
together with different techniques used for analyses of
antigen-specific responses, probably help to explain
some of the existing discrepancies with regard to which
cell populations and cytokine responses predominate in
lymphoid tissues and target organs during CIA [45-50].
Further analysis using the currently described animal
model may help elucidate some of these matters. We
have successfully used the B22a1 antibody for immuno-
histochemical identification of B22a1
+ T cells in lymph
nodes and spleens of CII-primed Vb12-tg mice (data not
shown), and we are currently investigating the possibility
to stain T cells residing in joints of arthritic animals.
Conclusions
Because of the increased precursor frequency of CII-spe-
cific T cells in the Vb12-tg mouse and the availability of
an antibody recognizing the majority of these cells, the
currently described animal model offers a unique possi-
bility to further elucidate the role of CII-specific T cells
as well as their different subsets during the development
and regulation of CIA at different time points and in
different tissues. The B22a1 antibody allows for highly
sensitive analysis of joint-residing T cells specific for
galactosylated CII by flow cytometry, due to its specifi-
city and relatively strong affinity to its cognate TCR,
compared with MHC class II tetramers.
Additional material
Additional file 1: B22a1 antibody does not bind to T cells with
other tested specificities than CII. Wildtype mice were immunized
with either pepsin or ovalbumin (OVA) emulsified in CFA. Seven days
later, draining lymph node cells were restimulated in vitro with the
immunogenic protein (third and fourth upper graphs from the left) as
well as with purified protein derivate (tuberculin-purified protein
derivative (PPD), mycobacterial antigens included in CFA; second upper
panel from the left) or left unstimulated (upper left panel). After 6 hours
of restimulation, cells were recovered and stained for expression of CD4,
CD154 and B22a1. The A
q-restricted pepsin-specific T-cell hybridoma HP1
was tested for staining with the B22a1 antibody (lower right panel), and
staining of the 22a1-7E T-cell hybridoma clone was stained in parallel as
positive control (lower left panel). Representative graphs for each
restimulation condition is shown and numbers within the quadrants of
the upper graphs shows the mean ± standard error of the mean of
three individual mice per group immunized and restimulated in vitro
with either pepsin or OVA and of all six mice restimulated in vitro with
PPD or left unstimulated.
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